Iranian Journal of Pathology

Evaluation of Notch1 and CD10 Expressions in Colorectal Carcinoma and Their Relationship with Prognosis

Document Type : Original Research

Authors

Noha Elkady 1
Reham Ahmed Abdelaziz 2
Rania Abdallah 1

1 Pathology Department, Faculty of Medicine, Menoufia University, Shibin Elkom, Menoufia, Egypt

2 Clinical Oncology and Nuclear medicine Department Faculty of Medicine, Menoufia University, Shibin Elkom, Menoufia, Egypt

https://doi.org/10.30699/ijp.2024.2029781.3304
Abstract
Background & Objective: Even with improvements of colorectal cancer (CRC) treatment strategies, this cancer still has an unfavorable outcome. The primary cause of CRC development and recurrence is chemoresistance. CD10 and Notch1 are among cancer stem cell regulators, and they have roles in cancer progression and chemoresistance. This research aims to evaluate the expression of Notch1 and CD10 in CRC and their relationship with different clinicopathological parameters using immunohistochemistry.
Methods: This retrospective study included 100 cases of colorectal carcinoma that were immunohistochemically stained using Notch1 and CD10 antibodies. Expression of Notch1 and CD10 was evaluated and compared with different clinicopathological parameters.
Results: Notch1 expression was detected in the tumor and stromal cells in 92% of the cases, while CD10 expression was seen in 31% of tumor cells 79% of stromal cells of the included cases. Their expressions in tumor cells were significantly associated with higher grade (P=0.029 and 0.001), deeper invasion (P=0.01 and 0.002), advanced stage (P=0.012 and 0.001), and distant metastasis (P=0.001 and 0.02). Notch1 expression was positively correlated with CD10 expression (P=0.018). Both Notch1 expression and high CD10 expression in the stromal cells were associated with short overall survival (P=0.003 and 0.01).
Conclusion: CD10 and Notch1 may have roles in colorectal carcinoma progression via induction of tumor invasion, metastasis and impairment of tumor response to therapy. CD10 and Notch1 could be used as biomarkers for aggressive CRC and may be considered for future target therapy.

Highlights

  • Notch1 and CD10 are significantly expressed in colorectal carcinoma (CRC).
  • Notch1 and CD10 expressions are associated with CRC progression and metastasis.
  • Notch1 and CD10 expressions are associated with impaired tumor response to therapy
  • Notch1 and CD10 may be considered for future target therapy in colorectal carcinoma

Keywords

Colorectal carcinoma
Notch1
CD10
progression

Subjects

  1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233-54. [DOI:10.3322/caac.21772] [PMID]
  2. Makhlouf NA, Muhammad A, Aya M, Sameh A, Mariam Z, Ahmed E, et al. Colorectal cancer in the Arab world: a systematic review. World J Gastrointest Oncol. 2021;13(11):1791-8. [DOI:10.4251/wjgo.v13.i11.1791] [PMID]
  3. Marin JJ, Sanchez de Medina F, Castaño B, Bujanda L, Romero MR, Martinez-Augustin O, et al. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab Rev. 2012;44(2):148-72. [DOI:10.3109/03602532.2011.638303] [PMID]
  4. De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. World J Gastroenterol. 2014;20(41):15049-59. [DOI:10.3748/wjg.v20.i41.15049] [PMID]
  5. Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond). 2012;7(4):597-615. [DOI:10.2217/nnm.12.22] [PMID]
  6. Fukusumi T, Ishii H, Konno M, Yasui T, Nakahara S, Takenaka Y, et al. CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma. Br J Cancer. 2014;111(3):506-14. [DOI:10.1038/bjc.2014.289] [PMID]
  7. Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue: a review. Diagn Pathol. 2014;9:221. [DOI:10.1186/s13000-014-0221-9] [PMID]
  8. Vuik FER, Nieuwenburg SAV, Bardou M, Valkhoff VE, Van Hevelingen M, Zadnik V, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut. 2019;68(10):1820-6. [DOI:10.1136/gutjnl-2018-317592] [PMID]
  9. Montminy EM, Zhou M, Maniscalco L, Heda R, Kim MK, Patel SG, et al. Shifts in the proportion of distant stage early-onset colorectal adenocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2022;31(2):334-41. [DOI:10.1158/1055-9965.EPI-21-0611] [PMID]
  10. Aster JC, Pear WS, Blacklow SC. The varied roles of Notch in cancer. Annu Rev Pathol. 2017;12:245-75. [DOI:10.1146/annurev-pathol-052016-100127] [PMID]
  11. Zhu H, Zhou X, Redfield S, Lewin J, Miele L. Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am J Transl Res. 2013;5(3):368-78. [DOI:10.1158/1538-7445.AM2013-410] [PMID]
  12. Zhou L, Zhang N, Song W, You N, Li Q, Sun W, et al. The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma. PLoS One. 2013;8(2): e57382. [DOI:10.1371/journal.pone.0057382] [PMID]
  13. Wang Z, Li Y, Kong D, Sarkar FH. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 2010;11(6):745-51. [DOI:10.2174/138945010791170860] [PMID]
  14. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66(5):2778-84. [DOI:10.1158/0008-5472.CAN-05-4281] [PMID]
  15. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007;7:3. [DOI:10.1186/1471-2490-7-3] [PMID]
  16. Thomas S, Babu RJ, Agarwal K, Puri V, Jain M, Andley M, et al. Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer - a preliminary study. Indian J Cancer. 2013;50(1):46-51. [DOI:10.4103/0019-509X.112299] [PMID]
  17. Huang WB, Zhou XJ, Chen JY, Zhang LH, Meng K, Ma HH, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol. 2005;35(5):245-50. [DOI:10.1093/jjco/hyi076] [PMID]
  18. Stivarou T, Patsavoudi E. Extracellular molecules involved in cancer cell invasion. Cancers (Basel). 2015;7(1):238-65. [DOI:10.3390/cancers7010238] [PMID]
  19. Jaako K, Waniek A, Parik K, Klimaviciusa L, Aonurm-Helm A, Noortoots A, et al. Prolyl endopeptidase is involved in the degradation of neural cell adhesion molecules in vitro. J Cell Sci. 2016;129(20):3792-802. [DOI:10.1242/jcs.181891] [PMID]
  20. Cho S, Lu M, He X, Ee PL, Bhat U, Schneider E, et al. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A. 2011;108(51):20778-83. [DOI:10.1073/pnas.1019452108] [PMID]
  21. Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841-56.e16. [DOI:10.1016/j.cell.2018.01.009] [PMID]
  22. Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8(35): 59950-64. [DOI:10.18632/oncotarget.19048] [PMID]
  23. Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:5416923. [DOI:10.1155/2018/5416923] [PMID]
  24. Maguer-Satta V, Roger B, Elodie B. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29(3):389-96. [DOI:10.1002/stem.592] [PMID]
  25. Wang Y, Li Q, Xu L, Chen J, Pu Y, Wang L, et al. Cancer stemness of CD10-positive cells regulated by Hedgehog pathway promotes the resistance to cisplatin in oral squamous cell carcinoma. Oral Dis. 2021;27(6): 1403-11. [DOI:10.1111/odi.13673] [PMID]
  26. Kenny AJ, O'Hare MJ, Gusterson BA. Cell-surface peptidases as modulators of growth and differentiation. Lancet. 1989;2(8666):785-7. [DOI:10.1016/S0140-6736(89)90841-6] [PMID]
  27. Karlsson C, Brantsing C, Egell S, Lindahl A. Notch1, Jagged1, and HES5 are abundantly expressed in osteoarthritis. Cells Tissues Organs. 2008;188(3):287-98. [DOI:10.1159/000121610] [PMID]
  28. Wilkin MB, Baron M. Endocytic regulation of Notch activation and down-regulation (review). Mol Membr Biol. 2005;22(4):279-89. [DOI:10.1080/09687860500129778] [PMID]
  29. Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369(1):20-7. [DOI:10.1016/j.canlet.2015.07.048] [PMID]
  30. Mizutani N, Abe M, Kajino K, Matsuoka S. A new CD10 antibody inhibits the growth of malignant mesothelioma. Monoclon Antib Immunodiagn Immunother. 2021;40(1):21-7. [DOI:10.1089/mab.2020.0033] [PMID]
Iranian Journal of Pathology
Volume 20, Issue 1
Winter 2025
Pages 68-75

  • Receive Date 21 May 2024
  • Revise Date 01 July 2024
  • Accept Date 19 October 2024

Home

Guide for Authors

Submit Manuscript

Contact Us